Good MorningEquity markets reversed course on Thursday giving up all of the gains from the prior day. The relief rally sparked by the FOMC was met by another round of selling driven by fear the Fed isn't acting fast enough and that inflation will continue to be a problem. The S&P 500 fell more than 4% at the low of the day led by the tech sector. The tech-heavy NASDAQ Composite fell more than 5% at the low of the day and will likely fall farther on Friday due to fear of next week's CPI data.
The CPI should moderate versus last year due to the YOY comparison. The risk for the market is that it won't and there are signs it will be hot regardless of the comparison. What this means for the market is that FOMC members may bring a 75 basis point hike back to the table and it could come as soon as June. Until then, the outlook for 2nd half economic activity and earnings growth is very cloudy with mounting risks. Featured: He started with $2,000. Now he's at $3 million. (Ad) 
|
Consumer Discretionary | |
Despite both companies delivering positive earnings, the tape is telling two different stories
In this article, we’re going to look at Expedia (NASDAQ:EXPE) and Booking Holdings (NASDAQ:BKNG). These are two of the titans of the travel sector. Both reported earnings this week so it’s ... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Consumer Discretionary | |
Papa John’s Raises Its Long Term Targets
Shares of Papa John’s (NASDAQ: PZZA) have been in a correction for the last few quarters on concerns about valuation. The stock is still trading above 25X its earnings but the bottom may be in. While the current results appear to be well price... Read the Full Story |
|
Markets | |
Many companies offer dividends to shareholders, which communicates the strength of the company and also allows companies to share their profits with shareholders. In essence, sharing their profits allows companies to "thank" their shareholders by providing a steady stream of income in the form of ... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Consumer Discretionary | | High-Yield Value Stock Kellogg Moves Up On Raised Guidance
Kellogg Company (NYSE: K) proved without a doubt that it and the consumer staples sector have pricing power. The company proactively raised its prices and was able to drive not only top-line growth but also margin preservation. In a world ... Read the Full Story |
|
Consumer Discretionary | |
Etsy Tailwinds Weaken, Shares Plummet
This is not the end of eCommerce or Etsy (NASDAQ: ETSY) but the boost to eCommerce provided by the pandemic is long past and the market has peaked. Esty is still growing but at the slowest pace since the pandemic began and the analysts are taking note. At le... Read the Full Story |
|
From Our Partners | | A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares still trade under 1 dollar.
It just signed the largest transaction in its history, a new gold streaming deal backed by a strategic relationship with a major mining investment firm.
A well-known sector financier has invested his own money and joins the CEO in an exclusive interview breaking down the full story. | | Click here for instant access to the free report now |
|
Industrials | |
If you thought ride-hailing app Uber (NYSE: UBER) was going to deliver the stock market from the horrendous start to the years it's had, think again. The likes of Apple (NASDAQ: AAPL) and Microsoft (NASDAQ: MSFT), who both reported solid numbers last week, were unable to stem the flow of selling, ... Read the Full Story |
|
Markets | | Sports entertainment and media company World Wrestling Entertainment (NYSE: WWE) stock has maintained a choppy range between $45 to $65 for over a year. The iconic wrestling brand survived the stay-at-home mandates to usher in the return of live events. Top and bottom lines were bolstered by its med... Read the Full Story |
|
Consumer Discretionary | |
Weyco Group Returns To Growth, Dividend Hike Is Expected
Weyco Group (NASDAQ: WEYS) caught our eye a few years ago while screening for small-cap dividend growth stocks. The company owns a healthy portfolio of legacy and growth-oriented shoe brands and pays what we consider to be an above-average... Read the Full Story |
|
Industrials | |
iRobot Moves Up On Fed “Soft Landing” Outlook
Shares of iRobot (NASDAQ: IRBT) have been in a steady downtrend for the last several quarters due to the mounting issues of supply chain hurdles and inflationary pressures. The biggest risk for the company and the global economy was the F... Read the Full Story |
|
Markets | | Internet content delivery network (CDN) provider Limelight Networks (NASDAQ: LLNW) shares plunged on its fiscal Q1 2022 earnings results. Despite have 19 of its top 20 customers achieving more than 20% revenue growth, sentiment turned negative with the falling benchmark indices. Customer additions h... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. | | View Today's Stock Pick |
|
